6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 Integrase Inhibitors

Although an extensive body of scientific and patent literature exists describing the development of HIV-1 integrase (IN) inhibitors, Merck’s raltegravir and Gilead’s elvitegravir remain the only IN inhibitors FDA-approved for the treatment of AIDS. The emergence of raltegravir-resistant strains of H...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Zhao, Xue Zhi, Maddali, Kasthuraiah, Smith, Steven J., Métifiot, Mathieu, Johnson, Barry C., Marchand, Christophe, Hughes, Stephen H., Pommier, Yves, Burke, Terrence R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523327/
https://ncbi.nlm.nih.gov/pubmed/23149229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2012.10.088
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk